[go: up one dir, main page]

MX2019008808A - Compuesto de pirimidina y su uso farmaceutico. - Google Patents

Compuesto de pirimidina y su uso farmaceutico.

Info

Publication number
MX2019008808A
MX2019008808A MX2019008808A MX2019008808A MX2019008808A MX 2019008808 A MX2019008808 A MX 2019008808A MX 2019008808 A MX2019008808 A MX 2019008808A MX 2019008808 A MX2019008808 A MX 2019008808A MX 2019008808 A MX2019008808 A MX 2019008808A
Authority
MX
Mexico
Prior art keywords
pharmaceutical use
pyrimidine compound
compound
pyrimidine
cancer
Prior art date
Application number
MX2019008808A
Other languages
English (en)
Other versions
MX378509B (es
Inventor
Jong Kang Seok
Hwan Bae In
Gil Ahn Young
Hyun Suh Kwee
Jin Ham Young
Yul Choi Jae
Hee KIM Seo
Woo Kim Tae
Original Assignee
Hanmi Pharma Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hanmi Pharma Co Ltd filed Critical Hanmi Pharma Co Ltd
Publication of MX2019008808A publication Critical patent/MX2019008808A/es
Publication of MX378509B publication Critical patent/MX378509B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Se proporcionan un compuesto de pirimidina representado por la Fórmula 1, un método para prepararlo y un uso farmacéutico del compuesto de pirimidina para la prevención o el tratamiento del cáncer.
MX2019008808A 2017-01-26 2018-01-26 Compuesto de pirimidina y su uso farmaceutico. MX378509B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR20170012766 2017-01-26
PCT/KR2018/001193 WO2018139903A1 (ko) 2017-01-26 2018-01-26 피리미딘 화합물 및 그의 의약 용도

Publications (2)

Publication Number Publication Date
MX2019008808A true MX2019008808A (es) 2019-09-16
MX378509B MX378509B (es) 2025-03-11

Family

ID=62979563

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2019008808A MX378509B (es) 2017-01-26 2018-01-26 Compuesto de pirimidina y su uso farmaceutico.

Country Status (22)

Country Link
US (2) US10280154B2 (es)
EP (2) EP3789386A1 (es)
JP (3) JP6608565B2 (es)
KR (1) KR101954369B1 (es)
CN (1) CN110214138A (es)
AR (1) AR110778A1 (es)
AU (1) AU2018211880B2 (es)
CA (1) CA3050239A1 (es)
DK (1) DK3514153T3 (es)
EA (1) EA039868B1 (es)
ES (1) ES2890668T3 (es)
HU (1) HUE056472T2 (es)
IL (2) IL290745B2 (es)
MX (1) MX378509B (es)
PH (1) PH12019501690A1 (es)
PL (1) PL3514153T3 (es)
PT (1) PT3514153T (es)
SA (1) SA519402288B1 (es)
SG (1) SG11201906435SA (es)
TW (1) TWI810172B (es)
WO (1) WO2018139903A1 (es)
ZA (1) ZA201905020B (es)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12325698B2 (en) 2018-07-25 2025-06-10 Hanmi Pharm. Co., Ltd. Pyrimidine compounds and pharmaceutical compositions for preventing or treating cancers including the same
US12350265B2 (en) 2019-06-27 2025-07-08 Hanmi Pharm. Co., Ltd. Pharmaceutical composition for treating acute myeloid leukemia, containing FLT3 inhibitor and chemotherapeutic agents
US12433867B2 (en) 2019-02-22 2025-10-07 Hanmi Pharm. Co., Ltd. Pharmaceutical composition comprising FLT3 inhibitor and hypomethylating agent for treating acute myeloid leukemia

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6608565B2 (ja) * 2017-01-26 2019-11-20 ハンミ ファーマシューティカルズ カンパニー リミテッド ピリミジン化合物及びその医薬用途
AU2019203034B1 (en) 2018-07-25 2019-09-26 Hanmi Pharm. Co., Ltd. Pyrimidine compounds and pharmaceutical compositions for preventing or treating cancers including the same
WO2020171649A1 (ko) * 2019-02-22 2020-08-27 한미약품 주식회사 Flt3 저해제 및 iap 길항제를 포함하는 급성 골수성 백혈병의 치료를 위한 약학적 조합물
EA202191984A1 (ru) * 2019-02-22 2021-11-19 Ханми Фарм. Ко., Лтд. Фармацевтическая композиция, содержащая ингибитор flt3 и гипометилирующий агент, для лечения острого миелолейкоза
CN111606889B (zh) * 2019-02-25 2023-03-07 上海翰森生物医药科技有限公司 4-(1-环丙基-1h-吲哚-3-基)-n-苯基嘧啶-2-胺衍生物的制备方法
CA3204401A1 (en) * 2021-01-07 2022-07-14 Rima AL-AWAR Isoindolinone aminopyrimidine compounds as inhibitors of nuak kinases, compositions and uses thereof
WO2023082052A1 (zh) * 2021-11-09 2023-05-19 暨南大学 环状2-氨基嘧啶类化合物及其用途
CN116102575B (zh) * 2021-11-09 2025-01-17 暨南大学 环状2-氨基嘧啶类化合物及其用途

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0500492D0 (en) * 2005-01-11 2005-02-16 Cyclacel Ltd Compound
WO2010042337A1 (en) * 2008-10-07 2010-04-15 Merck Sharp & Dohme Corp. Novel 6-azaindole aminopyrimidine derivatives having nik inhibitory activity
CN101723936B (zh) * 2008-10-27 2014-01-15 上海睿星基因技术有限公司 激酶抑制剂及其在药学中的用途
US20100105655A1 (en) * 2008-10-29 2010-04-29 Astrazeneca Ab Novel compounds 515
US20110005173A1 (en) * 2009-07-08 2011-01-13 Kraft Foods Global Brands Llc Method and Apparatus to Create a Contoured Flow Wrap Package
WO2011008915A1 (en) * 2009-07-15 2011-01-20 Abbott Laboratories Pyrrolopyridine inhibitors of kinases
UY33539A (es) * 2010-08-02 2012-02-29 Astrazeneca Ab Compuestos químicos alk
PL3009431T3 (pl) 2011-07-27 2018-02-28 Astrazeneca Ab Pochodne 2-(2,4,5-podstawionej-anilino) pirymidyny jako modulatory egfr użyteczne do leczenia nowotworu
WO2013146963A1 (ja) * 2012-03-28 2013-10-03 武田薬品工業株式会社 複素環化合物
WO2014155300A2 (en) * 2013-03-28 2014-10-02 Aurigene Discovery Technologies Limited Substitued pyrimidine amine derivatives as tak-1 inhibitors
ES2702951T3 (es) * 2014-04-04 2019-03-06 Syros Pharmaceuticals Inc Inhibidores de quinasas dependientes de ciclina 7 (cdk7)
WO2016029839A1 (zh) * 2014-08-25 2016-03-03 四川海思科制药有限公司 一种（取代的苯基）（取代的嘧啶）胺基衍生物及其制备方法和药物用途
LT3571192T (lt) * 2017-01-17 2023-02-27 Astrazeneca Ab Jak1 atžvilgiu selektyvūs inhibitoriai
JP6608565B2 (ja) * 2017-01-26 2019-11-20 ハンミ ファーマシューティカルズ カンパニー リミテッド ピリミジン化合物及びその医薬用途

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12325698B2 (en) 2018-07-25 2025-06-10 Hanmi Pharm. Co., Ltd. Pyrimidine compounds and pharmaceutical compositions for preventing or treating cancers including the same
US12433867B2 (en) 2019-02-22 2025-10-07 Hanmi Pharm. Co., Ltd. Pharmaceutical composition comprising FLT3 inhibitor and hypomethylating agent for treating acute myeloid leukemia
US12350265B2 (en) 2019-06-27 2025-07-08 Hanmi Pharm. Co., Ltd. Pharmaceutical composition for treating acute myeloid leukemia, containing FLT3 inhibitor and chemotherapeutic agents

Also Published As

Publication number Publication date
PL3514153T3 (pl) 2022-01-17
SA519402288B1 (ar) 2022-03-09
ZA201905020B (en) 2020-12-23
DK3514153T3 (da) 2021-09-27
NZ755325A (en) 2024-05-31
IL290745B1 (en) 2023-07-01
EP3514153A1 (en) 2019-07-24
JP6608565B2 (ja) 2019-11-20
KR20180088317A (ko) 2018-08-03
AR110778A1 (es) 2019-05-02
US20190031643A1 (en) 2019-01-31
EA201991580A1 (ru) 2020-02-03
PH12019501690A1 (en) 2020-03-09
AU2018211880A1 (en) 2018-09-13
CA3050239A1 (en) 2018-08-02
JP2019531315A (ja) 2019-10-31
JP7191799B2 (ja) 2022-12-19
MX378509B (es) 2025-03-11
SG11201906435SA (en) 2019-08-27
TW201829396A (zh) 2018-08-16
PT3514153T (pt) 2021-09-22
ES2890668T3 (es) 2022-01-21
IL268010A (en) 2019-09-26
EP3514153B1 (en) 2021-07-07
EP3514153A4 (en) 2020-04-29
TWI810172B (zh) 2023-08-01
KR101954369B1 (ko) 2019-03-05
WO2018139903A1 (ko) 2018-08-02
JP2020023554A (ja) 2020-02-13
EA039868B1 (ru) 2022-03-22
JP2023027203A (ja) 2023-03-01
US20190127353A1 (en) 2019-05-02
IL290745B2 (en) 2023-11-01
CN110214138A (zh) 2019-09-06
US10280154B2 (en) 2019-05-07
IL268010B (en) 2022-04-01
BR112019015256A2 (pt) 2020-04-14
HUE056472T2 (hu) 2022-02-28
AU2018211880B2 (en) 2019-04-11
IL290745A (en) 2022-04-01
JP7684002B2 (ja) 2025-05-27
US10519141B2 (en) 2019-12-31
EP3789386A1 (en) 2021-03-10

Similar Documents

Publication Publication Date Title
PH12019501690A1 (en) Pyrimidine compound and pharmaceutical use thereof
ZA201906832B (en) Novel psma-binding agents and uses thereof
ZA202100485B (en) Pyrimidine compounds and pharmaceutical compositions for preventing or treating cancers including the same
GEP20217211B (en) Substituted carbonucleoside derivatives useful as anticancer agents
TN2019000211A1 (en) Antitumoral compounds
PH12019500196A1 (en) Compounds and compositions and uses thereof
UA117976C2 (uk) Сполуки амінопіримідинілу як інгібітори jak
MY194468A (en) Oxy-fluoropiperidine derivatives as kinase inhhiitor
EP3778605A3 (en) Lrrk2 inhibitors and methods of making and using the same
GEP20186933B (en) Substituted dihydroisoquinoline compounds
MX2020006237A (es) Compuestos para el tratamiento de enfermedades relacionadas con la expresion de dux4.
AU2016380190A8 (en) Deuterated compounds for treating cancer and related diseases and conditions, and compositions and methods thereof
MX2020005659A (es) Uso de un inhibidor de parp en el tratamiento del cancer de ovario o cancer de mama resistente a la quimioterapia.
PH12019501955A1 (en) Tri-cycle compound and applications thereof
SA520411726B1 (ar) مشتق فينيل بيريدين جديد وتركيبة صيدلانية تشتمل عليه
PH12017501130A1 (en) Indenyl compounds, pharmaceutical compositions, and medical uses thereof
MX2019006863A (es) Inhibidores de heparanasa y uso de los mismos.
PH12019500198A1 (en) Compounds and compositions and uses thereof
PH12019500370A1 (en) Triazolopyrazinone derivative useful as a human pde1 inhibitor
SG11201803867TA (en) Sodium channel blocker
UA117524C2 (uk) Стимулятори рослин, їх застосування та спосіб стимуляції рослин
MY180727A (en) Tetrahydrofurane-fused aminohydrothiazine derivatives which are useful in the treatment of alzeimer?s disease
PH12017501560A1 (en) Tetrahydropyranyl benzamide derivatives
PH12018501100A1 (en) Phenylimidazole compound
IN2013DE03665A (es)